Information and calculation tools by Rachid Asen. Not investment advice or research.

Disclaimer. Information tool. Compiles data published by NSE and BSE and calculations from the exchanges' published ESM and ASM criteria. Prices are end-of-day, not live: updated each evening after trading ends. Ethical business criteria are matched by AI, which can make mistakes; this is a criteria match, not a certification, fatwa, rating or advice. Check the company's filings. Not investment advice, research or a recommendation to buy, sell or hold any security; not SEBI-registered as an Investment Adviser or Research Analyst. Calculated dates are the earliest a security could become eligible; inclusion, stage changes and exit are decided solely by the exchanges. ESM, ASM and GSM shortlisting are surveillance measures and not an adverse action against the company. Data may be delayed or inaccurate; verify with the exchange.

SurveillanceLabby Rachid AsenSupportSign in
Market closedPro tools are for Pro members only. Pro access requires signing an NDA.Pro needs an NDA.Request Pro accessRequest accessIST

Torrent Pharmaceuticals Limited

TORNTPHARM (NSE) · TORNTPHARM (BSE 500420) · ISIN INE685A01028 · Pharmaceuticals · Est. 1972 · listed 2002 · website

Not on any surveillance list Nifty 500 member

In Q2 FY27 (quarter to 30 September 2026, standalone), revenue was ₹4,145 cr and profit after tax ₹498 cr. Revenue was 50.1% higher than in Q2 FY26.

Open the full company file Every section, filings and your notes, in the app.

Quarterly results

Quarterly results, ₹ crore (as filed)
QuarterRevenueProfit after taxEPS (₹)Filed
Q2 FY27 standalone₹4,145 cr₹498 cr13.0923 Oct 2026
Q1 FY27 standalone₹4,158 cr₹492 cr12.9430 Jul 2026
Q4 FY26 standalone₹2,735 cr₹467 cr13.8023 May 2026
Q3 FY26 standalone₹2,599 cr₹577 cr17.0413 Feb 2026
Q2 FY26 standalone₹2,762 cr₹597 cr17.647 Nov 2025
Q1 FY26 standalone₹2,616 cr₹551 cr16.2828 Jul 2025
Q4 FY25 standalone₹2,433 cr₹474 cr14.0021 May 2025

Balance sheet

Balance sheet, ₹ crore (as filed)
As ofTotal equityBorrowingsTotal assets
30 Sep 2026 standalone₹18,256 cr₹13,135 cr₹42,061 cr
31 Mar 2026 standalone₹8,452 cr₹14,164 cr₹25,814 cr
30 Sep 2025 standalone₹8,455 cr₹1,994 cr₹13,325 cr

Shareholding

Shareholding pattern, Sep 2026
PromoterFIIDIIPublic
60.78%17.22%13.46%39.22%

Other companies in Pharmaceuticals

Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 23 October 2026.

Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.